Literature DB >> 3143890

Neisseria meningitidis group B serosubtyping using monoclonal antibodies in whole-cell ELISA.

H Abdillahi1, J T Poolman.   

Abstract

Meningococci can be classified by the presence of serotype and subtype antigens on the class 2/3 and class 1 outer membrane proteins, respectively. A typing system employing monoclonal antibodies and a WCE for detection of such antigens enabled us to sero- and/or subtype 255 out of 268 group B meningococci from 19 countries collected from 1959 till 1987. The combination of a comprehensive collection of antibodies and a sensitive, specific, large-scale screening technique greatly facilitates the assignment of bacterial isolates to their sero- or subtype. This will then allow definitive, bass-line information on the epidemiology of meningococci and on the possible construction of outer membrane protein vaccines.

Entities:  

Mesh:

Substances:

Year:  1988        PMID: 3143890     DOI: 10.1016/0882-4010(88)90045-9

Source DB:  PubMed          Journal:  Microb Pathog        ISSN: 0882-4010            Impact factor:   3.738


  47 in total

1.  Protection by meningococcal outer membrane protein PorA-specific antibodies and a serogroup B capsular polysaccharide-specific antibody in complement-sufficient and C6-deficient infant rats.

Authors:  Maija Toropainen; Leena Saarinen; Gestur Vidarsson; Helena Käyhty
Journal:  Infect Immun       Date:  2006-05       Impact factor: 3.441

2.  Clonal and antigenic analysis of serogroup A Neisseria meningitidis with particular reference to epidemiological features of epidemic meningitis in the People's Republic of China.

Authors:  J F Wang; D A Caugant; X Li; X Hu; J T Poolman; B A Crowe; M Achtman
Journal:  Infect Immun       Date:  1992-12       Impact factor: 3.441

3.  Specificity of human bactericidal antibodies against PorA P1.7,16 induced with a hexavalent meningococcal outer membrane vesicle vaccine.

Authors:  E R van der Voort; P van der Ley; J van der Biezen; S George; O Tunnela; H van Dijken; B Kuipers; J Poolman
Journal:  Infect Immun       Date:  1996-07       Impact factor: 3.441

4.  A meningococcal vaccine antigen engineered to increase thermal stability and stabilize protective epitopes.

Authors:  Monica Konar; Rolando Pajon; Peter T Beernink
Journal:  Proc Natl Acad Sci U S A       Date:  2015-11-16       Impact factor: 11.205

5.  Sequence variation in the porB gene from B:P1.4 meningococci causing New Zealand's epidemic.

Authors:  Kristin H Dyet; Diana R Martin
Journal:  J Clin Microbiol       Date:  2005-02       Impact factor: 5.948

6.  Monoclonal antibodies against the 70-kilodalton iron-regulated protein of Neisseria meningitidis are bactericidal and strain specific.

Authors:  A Pettersson; B Kuipers; M Pelzer; E Verhagen; R H Tiesjema; J Tommassen; J T Poolman
Journal:  Infect Immun       Date:  1990-09       Impact factor: 3.441

7.  Clonal analysis of the serogroup B meningococci causing New Zealand's epidemic.

Authors:  K H Dyet; D R Martin
Journal:  Epidemiol Infect       Date:  2006-04       Impact factor: 2.451

8.  Characterization of Neisseria meningitidis serogroup A strains from an outbreak in France by serotype, serosubtype, multilocus enzyme genotype and outer membrane protein pattern.

Authors:  J Y Riou; D A Caugant; R K Selander; J T Poolman; M Guibourdenche; E Collatz
Journal:  Eur J Clin Microbiol Infect Dis       Date:  1991-05       Impact factor: 3.267

9.  Conjugates of synthetic cyclic peptides elicit bactericidal antibodies against a conformational epitope on a class 1 outer membrane protein of Neisseria meningitidis.

Authors:  P Hoogerhout; E M Donders; J A van Gaans-van den Brink; B Kuipers; H F Brugghe; L M van Unen; H A Timmermans; G J ten Hove; A P de Jong; C C Peeters
Journal:  Infect Immun       Date:  1995-09       Impact factor: 3.441

10.  Necessity of molecular techniques to distinguish between Neisseria meningitidis strains isolated from patients with meningococcal disease and from their healthy contacts.

Authors:  U Vogel; G Morelli; K Zurth; H Claus; E Kriener; M Achtman; M Frosch
Journal:  J Clin Microbiol       Date:  1998-09       Impact factor: 5.948

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.